Subscribe to our Newsletters !!
Climate change is very disruptive to the Amazon ra
By 2024, there are certain things you need to do i
Insects that are given more attention and reverenc
Alembic Pharmaceuticals Limited appoints Mr. Manis
The importance of comparing the treatment of asthm
It is important to understand that natural remedie
Dear Readers, Welcome to the latest issue of The Magazine
Researcher from Scripps Research Institute recently discovered class of new drug order to help in increasing bone mass by expanding bone formation and bone turn over: Common process of replacement of old bone.
Typically Diabetes 2 is condition closely related with bone loss and fractures and certain diabetes drug helps in increasing this risk. Th study done by Patrick R. Griffin, a professor on the Florida campus of The Scripps Research Institute (TSRI), and B. Lecka-Czernik, a professor at the University of Toledo and found that a new class of drug candidate developed in TSRI increases bone mass by expanding the bone formation. The result is a new dual-targeting drug candidate–or, as Griffin describes, "one drug addressing multiple therapeutic indications"–that could treat both diabetes and bone disease. The compound has been referenced as "SR10171." This important research recently appears in current edition of EBioMedicine. According to survey results of 2012 by American Diabetes Association, Diabetes affects more than 29 million people in the United States while in between 2010 and 2012 the same ration was about 1.7 to 1.9 million per year.
According To Researcher, "Using structural biology techniques and rational design synthetic chemistry, SR10171 was constructed to engage the PPARγ protein in a unique way possessing an optimal balance with the receptor's other family member, PPARa, to treat diabetes and, at the same time, improve bone health," Griffin said. "This targeted polypharmacological approach demonstrates that the target isn't the problem if you target it correctly."
Story source:Scripps Research Institute
Journal References:
L.A. Stechschulte, P.J. Czernik, Z.C. Rotter, F.N. Tausif, C.A. Corzo, D.P. Marciano, A. Asteian, J. Zheng, J.B. Bruning, T.M. Kamenecka, C.J. Rosen, P.R. Griffin, B. Lecka-Czernik. PPARG Post-translational Modifications Regulate Bone Formation and Bone Resorption. EBioMedicine, 2016; DOI: 10.1016/j.ebiom.2016.06.040
